Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Senzime AB ( (SE:SEZI) ) has shared an update.
Senzime AB has expanded its agreements with a leading integrated delivery network in the southeastern US, securing an order for 65 additional TetraGraph neuromuscular monitoring systems. The expansion will bring the network’s installed base to more than 160 systems and is expected to generate over SEK 6 million in annual recurring revenue, underscoring growing adoption of Senzime’s technology in large hospital organizations.
The company reports that more than 5,000 TetraGraph units have now been delivered globally and its solutions are used in over 750 hospitals, positioning Senzime as an increasingly influential player in modern anesthesia practice. By enabling more precise dosing of neuromuscular blocking and reversal agents, the TetraGraph system supports improved patient safety and more cost-effective care, strengthening Senzime’s reference base and competitive standing in the perioperative monitoring market.
More about Senzime AB
Senzime AB is a Swedish medical device company that develops and markets precision-based monitoring systems to improve perioperative patient safety and reduce healthcare costs. Its flagship TetraGraph system, used in thousands of operating rooms worldwide, provides accurate monitoring of neuromuscular transmission during surgery to guide dosing of paralytic drugs and support safer anesthesia and recovery. Senzime is headquartered in Uppsala and listed on Nasdaq Stockholm, with additional trading on the US OTCQX market.
YTD Price Performance: -4.44%
Average Trading Volume: 222,691
Technical Sentiment Signal: Sell
Current Market Cap: SEK811.2M
For detailed information about SEZI stock, go to TipRanks’ Stock Analysis page.